For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction.
PURPOSE We evaluate the efficacy and safety of tadalafil , taken as needed , in men with mild to severe erectile dysfunction ( ED ) and assess sexual intercourse attempt patterns . MATERIAL S AND METHODS In this multicenter , double-blind , placebo controlled , parallel study conducted in the United States and Puerto Rico 207 men with ED were r and omized to placebo or 20 mg tadalafil for 12 weeks . The primary efficacy variables were changes from baseline in the mean International Index of Erectile Function erectile function domain score and mean per patient percentage of " yes " responses to Sexual Encounter Profile ( SEP ) diary questions 2 ( successful penetration ) and 3 ( successful intercourse ) . The Global Assessment Question was a secondary end point and post hoc analyses on sexual intercourse attempt patterns were conducted . RESULTS Men treated with  tadalafil  compared with placebo reported greater mean changes from baseline on the erectile function domain score ( 9.3 vs 0.3 with placebo , p < 0.001 ) and on the mean per patient percentage of successful penetration ( SEP question 2 , 31.6 % vs 2.3 % with placebo , p < 0.001 ) and successful intercourse attempts ( SEP question 3 , 43.6 % vs 3.5 % with placebo , p < 0.001 ) . The per treatment group percentage of successful intercourse attempts during treatment was higher for tadalafil than placebo ( 67.6 % vs 24.1 % , respectively , p < 0.001 ) and most successful intercourse attempts occurred between 4 and 36 hours after taking tadalafil . Of the men treated with tadalafil 82.8 % reported improved erections versus 19.6 % taking placebo ( Global Assessment Question , p < 0.001 ) . The most common treatment emergent adverse events were headache ( 15.7 % vs 6.3 % with placebo ) , back pain ( 8.8 % vs 0 % ) , and dyspepsia ( 7.5 % vs 0 % ) . CONCLUSIONS Tadalafil ( 20 mg ) significantly improved erectile function and patients did not closely temporally link sexual intercourse attempts with taking tadalafil . Tadalafil was also well tolerated in both groups of men with mild to severe ED
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .